Veracyte Inc (VCYT) Stock Analysis
Verdict: HOLD
Strong diagnostic cash flows and margin expansion offset short-term pullback risks, but high beta and insider selling warrant disciplined entry.
Investment score: 63/100
Analysis as of
Is Veracyte Inc stock worth reviewing? AI model thesis
The model score of 63/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Veracyte Inc opportunities and risks
What speaks for VCYT
- Expansion of Decipher and Afirma test volumes driving high-margin revenue growth
What speaks against VCYT
- Reimbursement cuts or coverage rollbacks by key healthcare payers
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VCYT | 27.5x | 5.6x | 22.4x | 72.1% | 20.4% | 5.2% |
| LEGN | n/a | 2.6x | n/a | 56.6% | -7.2% | -7.9% |
| ARQT | 114.4x | 6.8x | 73.4x | 91.1% | 6.1% | 1.2% |
| DYN | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.0% |
| DNLI | n/a | 904.7x | n/a | -61.0% | -14191.2% | -13.4% |
| RCUS | n/a | 27.2x | n/a | 94.0% | -386.3% | -14.9% |
| Peer median | n/a | 6.8x | n/a | 56.6% | -7.2% | -13.4% |
Frequently asked questions about Veracyte Inc (VCYT)
Is VCYT stock a good investment?
The cached TradeMates AI model rates Veracyte Inc as HOLD with an investment score of 63/100. The model score of 63/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is VCYT stock a buy?
The TradeMates model verdict for VCYT is HOLD with an investment score of 63/100. Treat this as a model signal to review, not a personal buy recommendation.